{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:33:49Z","timestamp":1789990429131,"version":"4.0.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.beha.2016.08.002","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T02:01:53Z","timestamp":1470967313000},"page":"90-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["TP53 dysfunction in CLL: Implications for prognosis and treatment"],"prefix":"10.1016","volume":"29","author":[{"given":"Gera D.","family":"te Raa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon P.","family":"Kater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2016.08.002_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/asheducation-2004.1.163","article-title":"Chronic lymphocytic leukemia","author":"Byrd","year":"2004","journal-title":"Hematology Am Soc Hematol Educ Progr"},{"key":"10.1016\/j.beha.2016.08.002_bib2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2016.08.002_bib3","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.002_bib4","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2016.08.002_bib5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2016.08.002_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2016.08.002_bib7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2016.08.002_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O'Brien","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2016.08.002_bib9","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/sj.leu.2404802","article-title":"The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia","volume":"21","author":"Kay","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.08.002_bib10","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2005-04-1677","article-title":"Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia","volume":"107","author":"Binet","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib11","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2004-11-4516","article-title":"Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL","volume":"106","author":"Austen","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib12","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib13","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2011.41.0852","article-title":"Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial","volume":"30","author":"Skowronska","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.002_bib14","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.002_bib15","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3109\/10428194.2013.783913","article-title":"Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?","volume":"54","author":"Rosenquist","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.08.002_bib16","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001016","article-title":"Clinical outcomes and correlates of TP53 mutations and cancer","volume":"2","author":"Robles","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.beha.2016.08.002_bib17","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood.V82.11.3452.3452","article-title":"p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1\/MDR3 gene expression","volume":"82","author":"El","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib18","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1073\/pnas.88.12.5413","article-title":"p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia","volume":"88","author":"Gaidano","year":"1991","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"10.1016\/j.beha.2016.08.002_bib19","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2016.08.002_bib20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1365-2141.2003.04265.x","article-title":"Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia","volume":"121","author":"Dewald","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.08.002_bib21","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184","article-title":"Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors","volume":"100","author":"Oscier","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib22","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2006.06.9492","article-title":"Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia","volume":"24","author":"Shanafelt","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.002_bib23","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2009-07-234708","article-title":"Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage","volume":"114","author":"Malcikova","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib24","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2008-04-154070","article-title":"Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up","volume":"112","author":"Zenz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib25","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/humu.22508","article-title":"TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia","volume":"35","author":"Malcikova","year":"2014","journal-title":"Hum Mutat"},{"key":"10.1016\/j.beha.2016.08.002_bib26","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","article-title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2016.08.002_bib27","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1200\/JCO.2010.32.0838","article-title":"Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial","volume":"29","author":"Gonzalez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.002_bib28","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1007\/s13277-014-2971-0","article-title":"TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods","volume":"36","author":"Kantorova","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.beha.2016.08.002_bib29","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/leu.2012.25","article-title":"ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia","volume":"26","author":"Pospisilova","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.08.002_bib30","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3109\/10428194.2013.829919","article-title":"The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia","volume":"55","author":"Stankovic","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.08.002_bib31","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2012.081620","article-title":"ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin","author":"Navrkalova","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.08.002_bib32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/leu.2014.196","article-title":"Recurrent mutations refine prognosis in chronic lymphocytic leukemia","volume":"29","author":"Baliakas","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.08.002_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.beha.2016.08.002_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.beha.2016.08.002_bib35","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib36","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2016.08.002_bib37","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3324\/haematol.2010.025338","article-title":"Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation","volume":"95","author":"Oscier","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.08.002_bib38","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib39","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib40","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","article-title":"Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial","volume":"114","author":"Zenz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib41","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2010-08-300160","article-title":"DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing","volume":"117","author":"Mohr","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib42","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/leu.2009.71","article-title":"Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction","volume":"23","author":"Mous","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.08.002_bib43","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1158\/1078-0432.CCR-11-2936","article-title":"Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration","volume":"18","author":"Lin","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2016.08.002_bib44","doi-asserted-by":"crossref","first-page":"e1852","DOI":"10.1038\/cddis.2015.223","article-title":"Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification","volume":"6","author":"te Raa","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.beha.2016.08.002_bib45","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3109\/10428194.2013.796058","article-title":"Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia","volume":"54","author":"te Raa","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.08.002_bib46","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.002_bib47","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)","volume":"100","author":"Lundin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib48","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","article-title":"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions","volume":"103","author":"Lozanski","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib49","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200208083470619","article-title":"Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy","volume":"347","author":"Stilgenbauer","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2016.08.002_bib50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bjh.13042","article-title":"A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53","volume":"167","author":"Shindiapina","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.08.002_bib51","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1182\/blood-2014-01-547737","article-title":"Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL","volume":"123","author":"Geisler","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib52","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1182\/blood.V122.21.2861.2861","article-title":"The impact of subclonal versus clonal novel recurrent mutations on treatment outcome in previously untreated high risk CLL patients: results from the HOVON68 trial. ASH abstract","volume":"122","author":"te Raa","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib53","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.13377","article-title":"The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed\/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy \u2013 the MD Anderson Cancer Center experience","author":"Thompson","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.08.002_bib55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","article-title":"Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus","volume":"21","author":"Dreger","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.08.002_bib56","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib57","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2016.08.002_bib58","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5s","key":"10.1016\/j.beha.2016.08.002_bib59","article-title":"ABT-199 (GDC-0199) in relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) AND small lymphocytic lymphoma (SLL): high complete-response rate and durable disease control","volume":"32","author":"Seymour","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.002_bib60","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1182\/blood-2014-07-586826","article-title":"Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?","volume":"124","author":"Dreger","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib61","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.beha.2016.08.002_bib62","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1182\/blood-2010-07-299321","article-title":"Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL.","volume":"117","author":"Christopoulos","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib63","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beha.2016.08.002_bib64","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib65","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjh.12115","article-title":"New ways to separate graft-versus-host disease and graft-versus-tumour effects after allogeneic haematopoietic stem cell transplantation","volume":"160","author":"Kotsiou","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.08.002_bib66","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib67","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib68","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.beha.2016.08.002_bib69","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2016.08.002_bib70","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2016.08.002_bib71","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood-2015-05-638338","article-title":"PD-L1 blockade: rejuvenating T cells in CLL","volume":"126","author":"Kater","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib72","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2015-01-622936","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib73","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1182\/blood-2010-01-043737","article-title":"Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor","volume":"116","author":"Jena","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib74","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2016.08.002_bib75","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood.V124.21.327.327","article-title":"Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE-17 trial","volume":"124","author":"O'Brien","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib76","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.beha.2016.08.002_bib77","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/blood.V122.21.1632.1632","article-title":"Clinical activity of ildelalisib (GS-1101), a selective inhibitor of PI3KP\u00e4, in phase 1 and 2 trials in chronic lymphocytic leukemia (CLL): effect of del(17p)\/TP53 mutation, del(11q), IGHV mutation, and NOTCH1 mutation","volume":"122","author":"Coutre","year":"2013","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2016.08.002_bib78","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood.V124.21.325.325","article-title":"Determination of recommended phase 2 dose of ABT-199 (GDC-0199) combined with rituximab (R) in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL)","volume":"124","author":"Roberts","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.002_bib79","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ajh.23964","article-title":"Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: results from a phase II study","volume":"90","author":"Doubek","year":"2015","journal-title":"Am J Hematol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T03:32:36Z","timestamp":1601004756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1521692616300044"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TP53 dysfunction in CLL: Implications for prognosis and treatment","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}